4363-13-7

Basic information

• Product Name: 3-phenylazetidine
• Synonyms: 3-phenylazetidine;OTAVA-BB 1179725;Azetidine, 3-phenyl-
• CAS NO: 4363-13-7
• Molecular Formula: C₉H₁₁N
• Molecular Weight: 133.193
• Mol File: 4363-13-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 226.8 °C at 760 mmHg
• Flash Point: 93.5 °C
• Appearance: /
• Density: 1.015 g/cm³
• Storage Temp.: 2-8°C(protect from light)
• PKA: 10.63±0.40(Predicted)
• CAS DataBase Reference: 3-phenylazetidine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-phenylazetidine(4363-13-7)
• EPA Substance Registry System: 3-phenylazetidine(4363-13-7)

Safety Data

• Hazardous Substances Data: 4363-13-7(Hazardous Substances Data)

Usage

Description

3-Phenylazetidine is a 3-substituted azetidine, a type of organic compound that belongs to the azetidine family. It is characterized by its unique chemical structure and properties, which contribute to its various applications in different industries.

Uses

Used in Pharmaceutical Industry:
3-Phenylazetidine is used as an active pharmaceutical ingredient for its analgesic and sympathomimetic effects. It is particularly effective in providing pain relief and stimulating the sympathetic nervous system, making it a valuable compound in the development of medications for various medical conditions.
Used in Research and Development:
3-Phenylazetidine is also utilized in the research and development of new drugs and therapies. Its unique chemical properties make it an interesting candidate for further study, potentially leading to the discovery of novel treatments for a range of health issues.

Upstream product

• 913814-30-9 1-(diphenylmethyl)-3-phenylazetidine 

Downstream Products

• 165611-90-5 (CO)5Cr(C(CH₃)NC₃H₅C₆H₅) 
• 927829-43-4 7-Chloro-6-(3-phenylazetidin-1-yl)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 
• 1312479-70-1 (2R)-2-methyl-2-(methylsulfonyl)-4-[2-oxo-4-(3-phenylazetidin-1-yl)pyridin-1(2H)-yl]-N-(tetrahydro-2H-pyran-2-yloxy)butanamide 
• 1621696-95-4 (E)-6-(3-oxo-3-(3-phenylazetidin-1-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one 
• 102178-22-3 (3-phenylazetidin-1-yl)(3,4,5-trimethoxyphenyl)methanone 
• 1451994-32-3 C₁₈H₁₈N₄OS 

Relevant articles and documents

Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides

Herein we describe the continued optimization of M4 positive allosteric modulators (PAMs) within the 5-amino-thieno[2,3-c]pyridazine series of compounds. In this letter, we disclose our studies on tertiary amides derived from substituted azetidines. This series provided excellent CNS penetration, which had been challenging to consistently achieve in other amide series. Efforts to mitigate high clearance, aided by metabolic softspot analysis, were unsuccessful and precluded this series from further consideration as a preclinical candidate. In the course of this study, we found that potassium tetrafluoroborate salts could be engaged in a tosyl hydrazone reductive cross coupling reaction, a previously unreported transformation, which expands the synthetic utility of the methodology.

AMINO-HETEROCYCLIC COMPOUNDS

The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, A, and n are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.